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Recombinant adenovirus vectors (Ad) have been recognized as effective in vivo gene delivery vehicles and utilized as
gene therapy agents for a number of cancers. The elucidation of viral entry mechanisms has allowed the development of
recombinant vectors that exploit existing cell surface receptors to achieve entry into the cell. B lymphocytes are normally
resistant to infection by adenovirus 5, likely due to the lack of the Coxsackie and Adenovirus receptor (CAR). Using reversetranscriptase PCR and flow cytometry, the CD40 receptor has been shown to be expressed on many lymphoma cells. We
exploited this finding to develop a gene therapy strategy for treatment of canine B-cell lymphoma. Ad5 was targeted
to cells expressing CD40 via CD40 ligand (CD40L) and was effective in infecting CD40-expressing control cells; however,
both primary canine lymphoma cells and cell lines demonstrated limited evidence of transduction. Following receptor
binding, adenovirus entry into cells may require interaction with αvβ3/5 integrins; we demonstrate that canine lymphoma
cells are deficient in these integrins. Reduced αvβ3 integrin expression may render these cells incapable of internalizing
Ad vectors. Thus, any viral targeting approaches for treatment of canine lymphoma must also take into account the
potential lack of internalization signals.

Introduction
The successful development of a gene therapy approach to B-cell
lymphoma requires the construction of vectors that specifically
target cancer cells and the use of an appropriate model for evaluation of these vectors. Canine lymphoma represents an excellent
model of human non-Hodgkin lymphoma. The canine disease
has a similar etiology and presentation to the human disease,
the model has an intact immune system and the size of the animal model allows for extrapolation to humans.1,2 Recombinant
Adenoviral (Ad) vectors derived from human serotypes 2 and 5
are the most promising vehicles for successful in vivo gene delivery, based on previously demonstrated efficiency in successful
gene delivery in a number of cancer gene therapy applications,
including gastric neoplasms and cancers of the head and neck.3,4

The use of adenoviral vectors for gene transfer has a number of
benefits: viral stocks can be produced easily and quickly, there
is robust gene expression with little risk of insertional mutagenesis, and infection and subsequent gene expression can occur in
quiescent cells.5 Potential limitations to the use of recombinant
adenoviruses as agents for gene therapy include the potential lack
of transduction of target tissue by Ad vectors due to the paucity of
native receptors on target cells, and the possibility of transfer to
normal cells as the native Ad receptor, CAR, is present on a wide
range of human tissue types.6,7
Entry of Ad into cells is a multi-step process, requiring
first the binding of the native CAR by the viral fiber knob,
followed by interaction of an RGD motif in the penton base
of Ad with αvβ3/5 integrins on the cell surface.8-10 Cells of the
lymphocyte lineage have proven refractory to Ad infection,
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Figure 1. (A) Transduction of CD40-positive cells by targeted vector. CD40-negative HEK293 cells and CD40-positive 293CD40 cells were infected with
either Ad5-ff-hCD40L or Ad5-ff-cCD40L at MOI of 10, 102 or 103 vp/cell. Transduction was indicated by luciferase activity; this was measured from cell
lysates and is reported as relative light units. Transduction increased with both vectors in both cell lines in a dose dependent manner; the highest level
of transduction as indicated by luciferase activity was seen with the Ad5-ff-hCD40L vector. The values were shown as relative infectivity by taking the
level of luciferase at 10 vp/cell as 100% and expressing other readings as relative percentage increase. (B) Incubation of cells with recombinant knob
blocked transduction by untargeted virus. Cells were incubated with recombinant knob to block CAR prior to infection with wt virus and luciferase
activity was used to measure transduction. In CD40-negative cells infected with wt virus, luciferase activity was reduced to 2% while in CD40-positive
cells infected with targeted virus, there was little reduction in transduction efficiency as determined by luciferase activity. Error bars indicate standard
deviation. *p < 0.05; ***p < 0.001.

which has been hypothesized to be due to the lack of cell surface expression of the primary Ad receptor CAR.11 Ad vectors
have been suggested as suitable vectors for transducing lymphocytes and CAR-expressing lymphocytes have demonstrated
efficient transduction by recombinant Ad.12,13 Ad has been used
in conjunction with a bispecific conjugate to achieve cell entry
in a CAR-independent fashion in human B lymphocytes via
CD70;14 murine B lymphocytes activated with lipopolysaccharide (LPS) were transduced with Ad modified to contain
a polylysine heparin binding motif in the fiber protein.15 This
same modification was also successful in transducing human
myeloma and myeloid leukemia cells in the presence of growth
factors.16 Therefore, the development of an adenoviral vector
to target B-cell lymphoma requires the modification of native
viral tropism either by modification of the viral capsid or by
the use of a bispecific conjugate that binds a cell surface receptor. To this end, CD40 was recognized as a potential candidate
molecule for retargeting. The CD40 molecule is expressed on B
lymphocytes and the interaction between CD40 and its ligand
promotes growth and differentiation of these cells.17
As a model for B-cell lymphoma targeted therapy, capsidmodified vectors retargeted to human and canine CD40 and a
bispecific conjugate comprised of the soluble CAR ectodomain
(sCAR) and CD40L were utilized. Both human- and caninederived cell lines and primary canine lymphoma cells were used
to evaluate the efficacy of the retargeted vectors in transducing
cells in a CAR-independent manner. The following report demonstrates the feasibility of retargeting Ad to CD40, and identifies that other cellular components necessary for internalization
of the vector may be lacking in canine lymphoma. In particular,
cells that lack αvβ3 integrins fail to internalize virus after it is
bound by the CD40-CD40L interaction.

Results
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Ad targeting to CD40-positive cells. In order to evaluate the efficiency of transduction with adenovirus particles targeting CD40
with CD40L, 293CD40 cells expressing canine CD40 were created. These cells and control parental HEK293 cells were used
to assess the ability to provide receptor-specific delivery to target
cells. Transduction by control and CD40 targeted vectors was
assessed by measuring the luciferase activity in cell lysates following incubation (Fig. 1A). Both HEK293 and 293CD40 cells
express CAR and were efficiently transduced by untargeted virus
with luciferase activity increasing in a dose-dependent manner
(data not shown). While transduction was achieved in both cell
lines with retargeted virus, the level of transduction in 293CD40
cells was higher than parental cells with either retargeted vector. To further demonstrate this transduction was achieved in a
CAR-independent manner, a recombinant knob protein which
binds to and blocks CAR was utilized. Incubation of cells with
recombinant knob blocked transduction of HEK293 cells with
wild-type (wt) virus, and luciferase activity was reduced to 2%
of that observed without blocking. By contrast, blocking with
recombinant knob prior to infection had less effect on 293CD40
cells. Luciferase activity remained almost unchanged at 94.7%
for Ad5-ff-hCD40L and 85% for Ad5-ff-cCD40L (Fig. 1B).
While the reduction in luciferase with the canine CD40L vector achieved statistical significance, it was far less of an effect
than was seen in HEK293 cells. This data indicates targeting
CD40 via CD40L is an effective method of redirecting adenovirus tropism, and that the interaction is specific to CD40 and does
not involve CAR. Additionally, this data suggests that human
CD40L may serve as a better ligand for canine CD40 than native
ligand.
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Figure 2. Expression of CD40 by lymphoma cell lines. The canine lymphoma cell lines OSW and 17–71 were analyzed for CD40 expression using antiCD40 monoclonal antibody by flow cytometry. Cells were incubated with a primary anti-CD40 monoclonal antibody labeled with Zenon Alexa 610/RPE.

CD40 mediated gene delivery in canine cell lines.
Following the success of targeting 293CD40 cells with
modified vectors, demonstration of this process in CD40
positive canine cell lines was attempted. Initial examination was performed in DH82, a canine histiocytoma line
determined to be CD40-positive by RT-PCR.26 These cells
were poorly infected by CD40 targeted virus. Subsequent
flow cytometry with anti-CD40 antibody showed these
cells to be devoid of cell-surface CD40 (data not shown).
Canine lymphoid lines OSW and 17–71 were then
obtained for this task. Both lymphoma cell lines were
shown to be CD40 positive by flow cytometry (Fig. 2). To
evaluate transduction with the retargeted vectors, OSW
and 17–71 cells were infected with Ad5, Ad5 ff hCD40L
and Ad5 ff cCD40L at MOIs ranging from 10–103 virus
particles per cell and incubated for 24 h. Both lymphoma
cell lines showed low-level transduction by wt virus at a
moi of 103 vp/cell indicated by luciferase activity. This was
Figure 3. Use of a bispecific adapter to increase CD40 targeted transduction in
approximately 10-fold higher in OSW cells than 17–71
lymphoma cell lines. Cell lines were infected with untargeted virus alone or in
cells. There was no transduction detected in either cell line
conjunction with a biphasic adapter targeted to CD40 (sCAR-CD40L) or a negain response to the retargeted vectors Ad5-ff-hCD40L or
tive control (sCAR-6His). The use of the targeted adapter increased transduction
Ad4-ff-cCD40L. The efficacy of the sCAR-CD40L biphain both cell lines and this was reduced to background levels with sCAR-6His. The
values were shown as relative infectivity by taking the level in untargeted virus
sic adapter in achieving gene transfer via CD40 was also
as 100% and expressing other readings as relative percentage change. Error
evaluated in these cell lines. Adaptor use increased luciferbars indicate standard deviation. ***p < 0.001.
ase expression 3.7-fold in OSW cells. To confirm that the
increase in luciferase expression was due to the interaction
of CD40L and CD40 and not via another viral component, the cells were analyzed by flow cytometry and chosen for transducsCAR-6His adapter was used as a negative control and luciferase tion experiments on the basis of positive CD21 and CD40 stainactivity was reduced below background levels (Fig. 3).
ing (Fig. 4). Cells isolated from five individual cases of primary
These experiments demonstrated canine lymphoma lines posi- lymphoma met these criteria and were tested. These cells were
tive for surface CD40 by flow cytometry were resistant to infection extracted from lymph nodes following excision and virus was
by CD40-targeted adenoviruses. Moderate levels of transduction added within 24 h of isolation. Cells were infected with control
were achieved, however, when these cells were infected with wt untargeted virus, targeted virus (Ad5-ff-hCD40L and Ad5-ffvirus and bispecific adapter.
cCD40L), and wt virus complexed with sCAR-hCD40L, incuCD40-mediated gene delivery in primary lymphoma cells. bated at 37°C at times ranging from 24–72 h, and then luciferase
Following experiments to demonstrate transduction of canine activity was measured. Two of the five cases showed no transcell lines via CD40, we attempted to transduce primary canine duction at any point; however, luciferase activity was detected in
lymphoma cells with the targeted viruses. Following isolation, three cases. In these three cases, the highest level of transduction
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Figure 4. CD21 and CD40 expression by primary canine lymphoma cells. Cells extracted from lymph nodes of canine patients diagnosed with lymphoma where transduction was attempted with retargeted vectors. Cells were stained with anti-CD40 antibody labeled with Zenon Alexa 610/RPE
and antiCD21 antibody labeled with Zenon Alexa 660. Top panel shows CD40, lower panel CD21.

achieved was with the use of the bispecific adapter plus wt virus
(Fig. 5). In dog 1, the use of the bispecific adapter with untargeted virus increased luciferase activity by 200-fold when compared to untargeted virus alone. While there was an increase in
transduction with the recombinant vectors Ad5-ff-hCD40L and
Ad5-ff-cCD40L compared to untargeted vectors (1.8- and 7-fold,
respectively), this was less dramatic. The level of transduction
with Ad5-ff-cCD40L was comparable to that observed in control
cells. In dog 2, transduction increased 54-fold with the bispecific
adapter plus untargeted virus, however, while transduction was
observed with the targeted viruses, it was less than that observed
with the wt virus and approximately 100-fold less than in control
cells in the case of Ad5-ff-hCD40L and 10-fold less with ad5ff-cCD40L. In dog 3, transduction was increased 4-fold with
the use of the bispecific adapter over wt alone, and again there
was very low luciferase activity in response to transduction with
Ad5-ff-hCD40L and none with Ad5-ff-cCD40L. Interestingly,
in both dogs 1 and 2, transduction was higher with the canine
CD40 targeted virus than with human sequence, which was an
effect opposite to that observed in control cells. Overall, this
data is consistent with that observed in OSW cells where transduction via the sCAR-CD40L adapter was more efficient than
retargeted viruses and retargeted Ad were much less efficient than
hypothesized.
The limited levels of transduction by CD40 targeted virus
observed in both primary canine lymphoma cells and canine lymphoma cell lines raises the potential for an absent component or
inoperative step in the viral entry pathway.

654

Integrin analysis of cell lines. The cellular uptake of Ad is a
multi-step process requiring viral binding to a cell surface receptor followed by interaction with surface integrins which mediate
internalization of the virus.8,10,15,27 Since there are differences in
cell line and primary cell transduction efficiencies, the role of αvβ3
integrin in adenoviral infection of canine lymphoma cells was
evaluated. The canine lymphoma cell lines OSW and 17–71 were
analyzed by flow cytometry for αvβ3 integrin levels to determine if
differential expression might help explain the disparities in transduction activity demonstrated between these cell lines (Fig. 6).
OSW cells have a detectable level of αvβ3, approximately 10-fold
above background; however, expression was much lower on 17–71
cells (approximately 2-fold). Primary lymphoma cell lines also
exhibited very low surface expression levels of integrin αvβ3. Thus,
low levels of αvβ3 integrin appear to be an obstacle to efficient
adenoviral infection of canine lymphoma cells.
Discussion
A major advance in the design of Ad vectors to treat tumors was
the development of methods to selectively transduce target cells
in a CAR-independent manner. This approach also circumvents
the lack of native CAR receptors on the surface of many tumor
cells, coupled with the need to de-target Ad from normal cells
that are susceptible to infection due to the presence of CAR.6,7,11
The results of the above experiments confirm most primary
canine B-cell lymphomas and many primary T-cell lymphomas
express high levels of CD40 on their surface making this protein
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attractive as a potential molecule for
retargeted antitumor Ad vectors.
Retargeting of Ad has been
demonstrated using a number of
approaches, including genetic modification of the fiber knob or the use
of bispecific adapters to redirect the
virus.28 In the experiments described
herein, successful retargeting of
Ad to CD40 using CD40L in the
293cCD40 cell line with capsidmodified virus was demonstrated.
However, CD40-positive lymphoma
cell lines and CD40-positive primary lymphomas proved generally
Figure 5. CD40-targeted transduction in primary cells. Three primary cultures of cells obtained from
resistant to transduction by modilymph nodes of lymphoma-affected dogs were infected within 24 h of collection with untargeted virus
fied Ad, with both OSW and 17–71
alone (control), untargeted virus and sCAR-CD40L, Ad5-ff-hDC40L or Ad5-ff-cCD40L and luciferase
cells showing no luciferase activity
activity was measured from cell lysates. The values were shown as relative infectivity by taking the
in response to infection with either
level of luciferase expression of Ad5 transduced cells as 100% and expressing other readings as relative
Ad5-ff-hCD40L or Ad5-ff-cCD40L
percentage change. Error bars indicate standard deviation. ***p < 0.001.
at a range of MOIs. No luciferase
activity was present in the majority of primary lymphoma cells has demonstrated αvβ3 integrins in neoplastic B lymphocytes can
infected, with only one case showing moderate luciferase expres- be upregulated following engagement of CD40 with its ligand.
sion following infection with Ad5-ff-cCD40L. The use of an This interaction leads to a five-fold increase in Ad-mediated gene
sCAR-CD40L bispecific adapter complexed with wt Ad5 was transfer in these cells.29 Additionally, B-lymphocyte proliferation
more efficient at transducing cells in the OSW cell line and two has been demonstrated following CD40-CD40L interaction in
of the primary canine cell cultures.
the presence of IL-4.31,32 As the experiments were conducted in
As canine B-cell lymphoma cells, proven to express adequate cells extracted from lymph nodes and were not enriched for B
levels of CD40, are refractory to infection with CD40 targeted lymphocytes, the combination of the CD40-CD40L engagement
Ad vectors, the failure of infection must be due to some mecha- in this multi-cellular environment, with the potential release of
nism occurring after initial binding of the virus to the cell surface. endogenous growth factors, may have contributed to the upreguPotential points of infection failure may include virus internaliza- lation of cell surface proteins necessary for viral internalization.
tion, un-coating, and/or nuclear trafficking. Virus internaliza- Although lymphoma cells have low levels of surface CAR, intertion has been shown to depend on the presence of cell surface action with other receptors, including the α2 domain of MHC
integrins, namely αvβ3/5 integrins,27 which may not be present class I molecules, have been implicated with virus binding,33
on some tumors. Human neoplastic B lymphocytes have been which may also indicate an increased ability of cells to internalshown to have low level expression of αvβ3 and αVβ5 integrins.29,30 ize Ad. Based on these studies, the retargeting of adenovirus to
Additionally, previous work has suggested that lack of integrin selectively transduce lymphoma cells will require overcoming
seems to be a crucial barrier to transducing B-lymphocyte cell the inability of these cells to internalize Ad based on a paucity
lines.30 While the level of αvβ3 integrin on canine lymphoma cells of cell surface integrins. Interestingly, in the above experiments,
was evaluated in this study, the lack of an available reagent pre- the bispecific sCAR adapter was found to be the most effective
vented examination of the expression of αvβ5 integrins.
method of achieving transduction in both lymphoma cell lines
The differing levels of αvβ3 integrin expression on the OSW and primary cells. The mechanism by which this is achieved
and 17–71 cell lines correlated with the transduction efficiency needs to be examined further and could be important in designof wt virus, alone and in conjunction with a bispecific adapter, in ing a targeted therapy for B-cell lymphoma.
these cells. This data suggests that, in this model, the expression
of αvβ3 integrin may play a role inensuring internalization of the
Methods
virus.
Our bispecific adapter molecule was partially successful trans- Cells lines and primary cells. HEK293 and DH82 (canine hisducing both cell lines and primary neoplastic cells. In fact, the tiocytic cell line) cells were purchased from ATCC and grown
highest level of luciferase activity detected was in two of the in DMEM/F12 supplemented with 10% fetal bovine serum
primary cell assays that had not been cryopreserved and were (FBS) (Hyclone), 1% antibiotic/antimycotic solution containinfected with wt Ad and the bispecific adapter sCARCD40L. ing penicillin, streptomycin and amphotericin (Cellgro), and
This may indicate that either the modified viruses are not as effi- grown at 37°C in 5% CO2. 293CD40 cells were created by stable
cient as wt at transducing cells, or the use of the bispecific adapter transfection of HEK293 cells with a linearized plasmid expressis responsible for this increased transduction. Previous research ing full-length canine CD40 cDNA. HEK293 cells were stably
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Figure 6. Expression of αvβ3 receptors on lymphoma cell lines and primary cells. Staining of αvβ3 receptors on OSW and17-71 cell lines and two of the
primary lymphoma cases where transduction was observed.

transfected with a pcDNA3 vector (Invitrogen, San Diego, CA)
into which a full-length cDNA amplicon of the canine CD40
open reading frame had been ligated. Amplicons were confirmed
for identity and sequence fidelity by direct DNA sequencing
(Auburn University DNA Sequencing Core) prior to ligation.
Plasmids were linearized outside the CD40 and Neo coding and
control regions prior to transfection and then transfected and
clones were selected in G418 media as previously described in
reference 18.
The OSW canine lymphoma cell line was provided by Dr.
William C. Kisseberth, The Ohio State University, and the
17–71 cell line was provided by Dr. Steven Suter, North Carolina
State University, and have been previously described in reference
19 and 20. These cell lines were grown in RPMI supplemented
with 10% FBS, 2 mM L-glutamine and 1% antibiotic/antimycotic solution and maintained at 37°C and 5% CO2.
Primary lymphoma cells were obtained by mechanical disruption of tissue obtained following excision of lymph nodes
surgically removed from untreated canine lymphoma patients
and submitted for histologic analysis as part of standard medical care. Briefly, lymph node tissue was placed in a sterile 6 cm
dish, with enough complete media (RPMI with 10% FBS, 2 mM
Glutamax, 1% antibiotic/antimycotic solution) to cover the tissue and cut into sections approximately 25 mm2. These pieces
were then passed through a sterile 70 μm nylon filter. Media
was added to a total of approximately 10 ml and the cells were
centrifuged at 250x g for 5 min. Cells were either re-suspended

656

in complete media and incubated at 37°C prior to infection or
analysis by flow cytometry or cryopreserved by re-suspending at
1 x 107 cells/ml in Gibco Recovery Cell Culture Freezing Media
(Invitrogen).
Flow cytometry. The following antibodies were used to detect
cell surface expression of receptors: rat anti-canine CD4-FITC
(clone YKIX302.9, AbD Serotec, Oxford UK), rat anti-canine
CD8-PE (clone YCATE55.9, AbD Serotec), mouse anti-canine
CD21 (Clone CA2.1D6, AbD Serotec) labeled with Zenon antimouse Alexa Fluor 610/R-PE (Invitrogen), mouse anti-human
CD40 antibody (Clone B-B20, Diaclone Bensancon, France)
labeled with Zenon anti-mouse Alexa Fluor 700 (Invitrogen),
mouse anti-human αvβ3 (Clone MAB1976, Millipore, Bellerica,
MA) conjugated to PE or labeled with Zenon anti-mouse Alexa
Fluor 700, and monoclonal antibody to human CAR RmcB (produced using a hybridoma purchased from ATCC and kindly provided by Joanne Douglas, University of Alabama, Birmingham,
AL). Cells were suspended (1 x 106) in 100 μl of staining buffer
(SB: PBS, 1% BSA, 0.1% sodium azide) and incubated for 20–30
min on ice. Antibodies were then added and cells incubated on
ice for 40–60 min in the dark. Following this incubation, cells
were washed two times in 2 ml PBS, and secondary antibodies were added at this stage if needed, followed by 40–60 min
incubation and 2x PBS wash. Cells were then re-suspended in
500 μl flow wash buffer (PBS, 0.1% BSA) and filtered to 50 μm
prior to analysis. All flow cytometry assays were performed on a
MoFlo Flow Cytometer and Cell Sorter (Beckman Coulter). The
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expression profiles were determined using Summit 4.3 software
(Beckman Coulter).
Adenovirus constructs. Luciferase-expressing vectors encoding artificial fiber proteins containing human (Ad5-ff-hCD40L)
or canine (Ad5-ff-cCD40L) CD40L were constructed as previously described in reference 21. Luciferase-expressing Ad5 vectors
encoding the native fiber protein were constructed as previously
described in reference 22 and 23.
All Ad5 vectors were isolated from infected HEK293 cells and
purified by equilibrium centrifugation in CsCl gradients according to a standard protocol.24 The protein concentrations in the
viral preparations were determined using the DC protein assay
(Bio-Rad, Hercules, CA) with purified bovine serum albumin
(BSA) as a standard. The virus titers were calculated using the
formula: 1 μg of protein = 4 x 109 viral particles (vp). The fusion
proteins sCAR-His6 and sCAR-CD40L were constructed as previously described in reference 25.
Gene transfer assays. Transduction by the panel of recombinant Ad5 vectors (Ad5CMV, Ad5-ff-hCD40L, Ad5-ff-cCD40L)
was examined using luciferase as the reporter gene. Cells were
grown in triplicate at a density of 1 x 105 cells/well in a 24 well
plate. Virus dilutions were made in multiplicities of infection
(moi) ranging from 101–104 vp/cell in media supplemented with
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